Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease

Clinical Drug Investigation

Volumn 21, Issue 7, 2001, Pages 485-497

  Mas R ^a   Castano G ^b   Fernandez L ^a   Illnait, J ^a   Fernandez J ^a   Alvarez, E ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Medical Surgical Research Center   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS;

EID: 0034913131     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121070-00004     Document Type: Article

References (63)

1. Heart attacks: Gone with the century?
2. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results I Reduction in the incidence of coronary heart disease
3. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results II The relationship on reduction in the incidence of coronary heart disease to cholesterol lowering
4. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
5. Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
10. Hypercholesterolemia in elderly persons: Resolving the treatment dilemma
11. Clinical considerations regarding treatment of hypercholesterolemia in the elderly
12. Lipid metabolism and cardiovascular risk: Should hypercholesterolemia be treated in the elderly?
13. Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop
14. The value of risk factor modification in old age
15. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel
16. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers
17. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment
18. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia
19. One year study on the effect of policosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia
20. Effects of policosanol in hypertensive patients with type II hypercholesterolemia
21. Effects of policosanol on hypercholesterolaemic patients with disturbances on serum biochemical indicators of hepatic function
22. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
23. Effects of policosanol on primary hypercholesterolemia: A 3 years open follow-up
24. A long-term open study of the efficacy and tolerability of policosanol in patients with high global coronary risk
25. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
26. Treatment of hypercholesterolemia in NIDDM with policosanol
27. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study
28. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts
29. Cholesterol-lowering effect of policosanol on rabbits with hyper-cholesterolemia induced by a wheat starch-casein diet
30. Acute, subchronic and chronic toxicology of policosanol in rats. Abstract of the 6th International Congress of Toxicology, Rome, 28 June-3 July 1992
31. Policosanol: A study of its genotoxicity and teratogenicity in rodents. Abstract of the 6th International Congress of Toxicology, Rome, 28 June-3 July 1992
32. Toxicity of policosanol in Beagle dogs: One year study
33. A 12 months study of policosanol oral toxicity in Sprague-Dawley rats
34. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 months study
35. Carcinogenicity of policosanol in mice: An 18 months' study
36. Teratogenic and reproductive studies of policosanol in the rat and rabbit
37. Multigeneration reproduction study of policosanol in rats
38. Evaluation of peri- and post-natal toxicity of policosanol in rats
39. Effects of policosanol in elderly hypercholesterolaemic patients
40. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12 months' study
41. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
42. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk
43. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
44. Pharmacoepidemiologic study of policosanol
45. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride
46. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifuge
47. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
48. Treating to LDL-C target: Resource utilization with atorvastatin compared with fluvastatin, pravastatin and simvastatin in patients with CHD
49. Prevention of coronary heart disease in clinical practice
50. LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid goals
51. The Scandinavian Simvastatin Survival Study (4S)- Chapter 2 in cholesterol-lowering therapy
52. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year treatment
53. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study
54. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
55. Efecto del policosanol sobre la función de las plaquetas en voluntarios sanos
56. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients
57. Effect of policosanol on platelet aggregation in healthy volunteers
58. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation
59. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
60. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation
61. Effects of policosanol on atherosclerosis lesions in rabbits with exogenous hypercholesterolemia
62. Pulse pressure and mortality in older people